186 related articles for article (PubMed ID: 32653696)
1. Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
Roussel E; Moréno A; Altounian N; Philouze C; Pérès B; Thomas A; Renaudet O; Falson P; Boumendjel A
Eur J Med Chem; 2020 Sep; 202():112503. PubMed ID: 32653696
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the chromone scaffold through QSAR and docking studies: Identification of potent inhibitors of ABCG2.
Roussel E; Tran-Nguyen VK; Bouhedjar K; Dems MA; Belaidi A; Matougui B; Peres B; Azioune A; Renaudet O; Falson P; Boumendjel A
Eur J Med Chem; 2019 Dec; 184():111772. PubMed ID: 31630055
[TBL] [Abstract][Full Text] [Related]
3. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of 5-Hydroxy-3',4',7-trimethoxyflavone and Related Compounds and Elucidation of Their Reversal Effects on BCRP/ABCG2-Mediated Anticancer Drug Resistance.
Tsunekawa R; Katayama K; Hanaya K; Higashibayashi S; Sugimoto Y; Sugai T
Chembiochem; 2019 Jan; 20(2):210-220. PubMed ID: 30187992
[TBL] [Abstract][Full Text] [Related]
5. 6-halogenochromones bearing tryptamine: one-step access to potent and highly selective inhibitors of breast cancer resistance protein.
Valdameri G; Genoux-Bastide E; Gauthier C; Peres B; Terreux R; Winnischofer SM; Rocha ME; Di Pietro A; Boumendjel A
ChemMedChem; 2012 Jul; 7(7):1177-80. PubMed ID: 22615192
[No Abstract] [Full Text] [Related]
6. Uncompetitive nanomolar dimeric indenoindole inhibitors of the human breast cancer resistance pump ABCG2.
Guragossian N; Belhani B; Moreno A; Nunes MT; Gonzalez-Lobato L; Marminon C; Berthier L; Rocio Andrade Pires AD; Özvegy-Laczka C; Sarkadi B; Terreux R; Bouaziz Z; Berredjem M; Jose J; Di Pietro A; Falson P; Le Borgne M
Eur J Med Chem; 2021 Feb; 211():113017. PubMed ID: 33223263
[TBL] [Abstract][Full Text] [Related]
7. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
Valdameri G; Genoux-Bastide E; Peres B; Gauthier C; Guitton J; Terreux R; Winnischofer SM; Rocha ME; Boumendjel A; Di Pietro A
J Med Chem; 2012 Jan; 55(2):966-70. PubMed ID: 22165858
[TBL] [Abstract][Full Text] [Related]
8. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
Deng F; Ghemtio L; Grazhdankin E; Wipf P; Xhaard H; Kidron H
Mol Pharm; 2020 Jul; 17(7):2398-2410. PubMed ID: 32496785
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydroquinoline/4,5-Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2).
Vesga LC; Kronenberger T; Tonduru AK; Kita DH; Zattoni IF; Bernal CC; Bohórquez ARR; Mendez-Sánchez SC; Ambudkar SV; Valdameri G; Poso A
ChemMedChem; 2021 Sep; 16(17):2686-2694. PubMed ID: 33844464
[TBL] [Abstract][Full Text] [Related]
10. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
11. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
13. New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2.
Pires ADRA; Lecerf-Schmidt F; Guragossian N; Pazinato J; Gozzi GJ; Winter E; Valdameri G; Veale A; Boumendjel A; Di Pietro A; Pérès B
Eur J Med Chem; 2016 Oct; 122():291-301. PubMed ID: 27376492
[TBL] [Abstract][Full Text] [Related]
14. Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
Silbermann K; Li J; Namasivayam V; Stefan SM; Wiese M
Eur J Med Chem; 2021 Feb; 212():113045. PubMed ID: 33454462
[TBL] [Abstract][Full Text] [Related]
15. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
16. Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2.
Silbermann K; Shah CP; Sahu NU; Juvale K; Stefan SM; Kharkar PS; Wiese M
Eur J Med Chem; 2019 Feb; 164():193-213. PubMed ID: 30594677
[TBL] [Abstract][Full Text] [Related]
17. 2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2.
Krapf MK; Gallus J; Namasivayam V; Wiese M
J Med Chem; 2018 Sep; 61(17):7952-7976. PubMed ID: 30075623
[TBL] [Abstract][Full Text] [Related]
18. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
[TBL] [Abstract][Full Text] [Related]
19. An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms.
Zeng L; Li J; Zhang C; Zhang YK; Zhang W; Huang J; Ashby CR; Chen ZS; Chao H
Chem Commun (Camb); 2019 Mar; 55(26):3833-3836. PubMed ID: 30869688
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological assessment of new pyrimidopyrimidines as inhibitors of breast cancer resistance protein (ABCG2).
Dakhlaoui I; Vahdati S; Maalej E; Chabchoub F; Wiese M; Marco-Contelles J; Ismaili L
Bioorg Chem; 2021 Nov; 116():105326. PubMed ID: 34536930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]